Deacons advises local retail chain Lung Fung on its Main Board IPO
June, 2026 - Hong Kong, Hong Kong
Deacons’ Corporate Finance Practice Group advises Lung Fung Group Holdings Limited (SEHK Stock Code: 2290) in relation to its Main Board IPO in Hong Kong, seeking to raise up to HK$797.5 million (subject to the exercise of over-allotment option).
Lung Fung Group Holdings Limited is a leading Hong Kong-based chain retail store of beauty, health and pharmaceutical products. It ranked third among beauty, health and pharmaceutical product retailers in terms of retail sales value in Hong Kong; and it was the largest pharmaceutical product retailer by retail sales value in Hong Kong, and also the third largest pharmaceutical and health product retailer by revenue in Hong Kong, in its financial year ended 31 March 2025, according to a market research report commissioned by the company.
The company published its IPO prospectus on 28 May 2026. Dealings in its shares on the Main Board of the Hong Kong Stock Exchange are expected to commence on 5 June 2026.
Our team is led by Ronny Chow and Maynard Leung, Partners of our Corporate Finance Practice Group.
"We are thrilled to have helped Lung Fung achieve this important milestone," said Ronny. "As Hong Kong’s largest independent law firm, this further strengthens our proven track record of guiding domestic household brands through their Hong Kong IPOs, including, among others, ATAL (Analogue Holdings), EGL, Fulum, Hung Fook Tong, K Cash, Tai Hing, Tam Jai, and Wharf Real Estate."
